-
1
-
-
84882977045
-
Genetics and biomarkers in personalisation of lung cancer treatment
-
Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382: 720-731.
-
(2013)
Lancet
, vol.382
, pp. 720-731
-
-
Rosell, R.1
Bivona, T.G.2
Karachaliou, N.3
-
2
-
-
84883013481
-
Management of nonsmall-cell lung cancer: Recent developments
-
Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of nonsmall-cell lung cancer: recent developments. Lancet 382: 709-719.
-
(2013)
Lancet
, vol.382
, pp. 709-719
-
-
Reck, M.1
Heigener, D.F.2
Mok, T.3
Soria, J.C.4
Rabe, K.F.5
-
3
-
-
0034648765
-
Angiogenesis in cancer and other diseases
-
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
-
(2000)
Nature
, vol.407
, pp. 249-257
-
-
Carmeliet, P.1
Jain, R.K.2
-
4
-
-
73649112748
-
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels
-
Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, et al. (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
-
(2009)
Am J Pathol
, vol.175
, pp. 2159-2170
-
-
Falcon, B.L.1
Hashizume, H.2
Koumoutsakos, P.3
Chou, J.4
Bready, J.V.5
-
5
-
-
84875456598
-
Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy
-
Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE (2013) Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73: 1649-1657.
-
(2013)
Cancer Res
, vol.73
, pp. 1649-1657
-
-
Gerald, D.1
Chintharlapalli, S.2
Augustin, H.G.3
Benjamin, L.E.4
-
6
-
-
84868486023
-
Angiopoietins in angiogenesis
-
Fagiani E, Christofori G (2013) Angiopoietins in angiogenesis. Cancer Lett 328: 18-26.
-
(2013)
Cancer Lett
, vol.328
, pp. 18-26
-
-
Fagiani, E.1
Christofori, G.2
-
7
-
-
60549103097
-
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth
-
Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, et al. (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
-
(2009)
Cancer Res
, vol.69
, pp. 1324-1333
-
-
Nasarre, P.1
Thomas, M.2
Kruse, K.3
Helfrich, I.4
Wolter, V.5
-
8
-
-
84861820220
-
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
-
Felcht M, Luck R, Schering A, Seidel P, Srivastava K, et al. (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005.
-
(2012)
J Clin Invest
, vol.122
, pp. 1991-2005
-
-
Felcht, M.1
Luck, R.2
Schering, A.3
Seidel, P.4
Srivastava, K.5
-
9
-
-
84890667775
-
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy
-
Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, et al. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent anti-tumor, anti-angiogenic, and anti-metastatic efficacy. Clin Cancer Res.
-
(2013)
Clin Cancer Res
-
-
Kienast, Y.1
Klein, C.2
Scheuer, W.3
Raemsch, R.4
Lorenzon, E.5
-
10
-
-
60749096085
-
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
-
Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
-
(2009)
Nat Rev Mol Cell Biol
, vol.10
, pp. 165-177
-
-
Augustin, H.G.1
Koh, G.Y.2
Thurston, G.3
Alitalo, K.4
-
11
-
-
79956068289
-
Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2
-
Andersen S, Donnem T, Al-Shibli K, Al-Saad S, Stenvold H, et al. (2011) Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One 6: e19773.
-
(2011)
PLoS One
, vol.6
-
-
Andersen, S.1
Donnem, T.2
Al-Shibli, K.3
Al-Saad, S.4
Stenvold, H.5
-
12
-
-
68849097805
-
Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy
-
Naumnik W, Chyczewska E, Ossolinska M (2009) Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy. Cancer Invest 27: 741-746.
-
(2009)
Cancer Invest
, vol.27
, pp. 741-746
-
-
Naumnik, W.1
Chyczewska, E.2
Ossolinska, M.3
-
13
-
-
84881060020
-
Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: A bronchoalveolar lavage and serum study
-
Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013) Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 788: 341-348.
-
(2013)
Adv Exp Med Biol
, vol.788
, pp. 341-348
-
-
Naumnik, W.1
Naumnik, B.2
Niewiarowska, K.3
Ossolinska, M.4
Chyczewska, E.5
-
14
-
-
34447525629
-
Serum angiopoietin-2 as a clinical marker for lung cancer
-
Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, et al. (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132: 200-206.
-
(2007)
Chest
, vol.132
, pp. 200-206
-
-
Park, J.H.1
Park, K.J.2
Kim, Y.S.3
Sheen, S.S.4
Lee, K.S.5
-
15
-
-
16644376056
-
Overexpression of Ang-2 mRNA in non-small cell lung cancer: Association with angiogenesis and poor prognosis
-
Takanami I (2004) Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep 12: 849-853.
-
(2004)
Oncol Rep
, vol.12
, pp. 849-853
-
-
Takanami, I.1
-
16
-
-
0020396015
-
Toxicology and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
-
(1982)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.5
, Issue.6
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Davis, T.E.3
-
17
-
-
0035710746
-
-ΔΔCT method
-
DOI 10.1006/meth.2001.1262
-
Livak KJ, and Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 25:402-408 (Pubitemid 34164012)
-
(2001)
Methods
, vol.25
, Issue.4
, pp. 402-408
-
-
Livak, K.J.1
Schmittgen, T.D.2
-
18
-
-
33847056277
-
Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-A review of the literature
-
Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, et al. (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12: 201-210.
-
(2007)
Oncologist
, vol.12
, pp. 201-210
-
-
Araujo, A.1
Ribeiro, R.2
Azevedo, I.3
Coelho, A.4
Soares, M.5
-
19
-
-
81055157135
-
Non-small-cell lung cancer
-
Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, et al. (2011) Non-small-cell lung cancer. Lancet 378: 1727-1740.
-
(2011)
Lancet
, vol.378
, pp. 1727-1740
-
-
Goldstraw, P.1
Ball, D.2
Jett, J.R.3
Le Chevalier, T.4
Lim, E.5
-
20
-
-
84855168417
-
Adjuvant chemotherapy for resected non-small-cell lung cancer: Future perspectives for clinical research
-
Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, et al. (2011) Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res 30: 115.
-
(2011)
J Exp Clin Cancer Res
, vol.30
, pp. 115
-
-
Bonomi, M.1
Pilotto, S.2
Milella, M.3
Massari, F.4
Cingarlini, S.5
-
21
-
-
84875937242
-
Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies
-
Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31: 1039-1049.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1039-1049
-
-
Li, T.1
Kung, H.J.2
Mack, P.C.3
Gandara, D.R.4
-
22
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
-
23
-
-
84887257904
-
Targeting angiogenesis in advanced non-small cell lung cancer
-
Lammers PE, Horn L (2013) Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw 11: 1235-1247.
-
(2013)
J Natl Compr Canc Netw
, vol.11
, pp. 1235-1247
-
-
Lammers, P.E.1
Horn, L.2
-
24
-
-
84874095390
-
Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab
-
Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, et al. (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 929-937
-
-
Hegde, P.S.1
Jubb, A.M.2
Chen, D.3
Li, N.F.4
Meng, Y.G.5
-
25
-
-
84873545836
-
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors
-
Thomas M, Kienast Y, Scheuer W, Bahner M, Kaluza K, et al. (2013) A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One 8: e54923.
-
(2013)
PLoS One
, vol.8
-
-
Thomas, M.1
Kienast, Y.2
Scheuer, W.3
Bahner, M.4
Kaluza, K.5
-
26
-
-
84896497658
-
A phase i first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies
-
KP P, NG C, A P, L A, AS L, et al. (2011) A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology 29.
-
(2011)
Journal of Clinical Oncology
, pp. 29
-
-
Kp, P.1
Ng, C.2
As, L.3
-
27
-
-
84863138369
-
A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization
-
Palmer GM, Tiran Z, Zhou Z, Capozzi ME, Park W, et al. (2012) A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 165: 1891-1903.
-
(2012)
Br J Pharmacol
, vol.165
, pp. 1891-1903
-
-
Palmer, G.M.1
Tiran, Z.2
Zhou, Z.3
Capozzi, M.E.4
Park, W.5
-
28
-
-
80053463397
-
A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis
-
Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, et al. (2011) A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 18: 598-607.
-
(2011)
Microcirculation
, vol.18
, pp. 598-607
-
-
Rennel, E.S.1
Regula, J.T.2
Harper, S.J.3
Thomas, M.4
Klein, C.5
|